Takeda Licenses CellCentric's Technologies | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Takeda Pharmaceutical Company has licensed from CellCentric cancer-related epigenetic target technologies for development and commercialization.

Under the agreement, Takeda's Research Group will conduct therapeutic research on molecules that will be further developed by Millenium, the biopharmaceutical firm that Takeda acquired in 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.